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A synthetic 27-residue peptide corresponding to exon 1 B of the endogenous inhibitor calpastatin contains a well-conserved region and has an ability 
to inhibit the cysteine ndopeptidase calpain specifically. We examined the solution structure of this peptide in DMSO-d, by two-dimensional ‘H 
NMR spectroscopy. Although regular secondary structures uch as a-helix and P-sheet were not found, the region from BeI to ArgZ3 formed a 
well-defined structure with a type I B-turn. This region coincided well with the highly conserved region of calpastatin. The result strongly suggests 
that this turn structure is essential for the inhibitory activity of calpastatin. 
Human calpastatin; Calpain; ‘H NMR; Structure in solution 
1. INTRODUCTION 
The cysteine protease calpain (EC 3.4.22.17) is 
strongly and specifically inhibited by the endogenous 
protein calpastatin. Though both calpain and calpa- 
statin are known to be common in animal cells [l-3] and 
are expected to play important roles in various cellular 
functions coupled with calcium-ion mobilization [4-81, 
nothing is known about how they interact with each 
other. 
Calpastatin with about 700 residues contains four 
internally repetitive sequences (Domains l-4) and one 
non-homologous equence at the amino-terminal end 
(Domain L), each consisting of approximately 140 resi- 
dues [9-l 11. Each domain has three well-conserved re- 
gions located on separate xons, A,B and C, of which 
exon B is essential and strongly inhibits calpains I and 
II [12]. So far, no X-ray crystallography has been car- 
ried out on calpastatin or its domains. CD and ‘H NMR 
studies of Uemori et al. [ 131 strongly suggested that the 
repetitive domain is disordered in aqueous solution. 
Available knowledge of serine protease inhibitors [14] 
and also of cystatin, a cysteine protease inhibitor the 
crystal structure of which has recently been determined 
Abbreviations: CD, circular dichroism; ‘H NMR, proton nuclear 
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hauser effect spectroscopy. 
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[ 151, indicate that certain well-defined structures are re- 
quired for these protease inhibitors to bind specifically 
to target enzymes. The reported lack of well-defined 
structure for the repetitive domain of calpastatin [13] is 
rather puzzling from this viewpoint. 
In the present work, using ‘H NMR, we studied the 
conformation of a synthetic oligopeptide of 27 residues 
corresponding to exon B in Domain 1 (exon IB) in 
DMSO-d6. This peptide contains the highly conserved 
region and retains a strong inhibitory potency against 
calpain (& = lo-’ M) in spite of its size constituting 
only one-fifth of the repetitive domain [ 161. It is naturai 
to expect that this indispensable peptide fragment will 
assume a certain defined structure at least when it binds 
to calpain. We chose DMSO-d, as a solvent, expecting 
that, to some extent, it will represent a somewhat hy- 
drophobic environment for the inhibitor binding site. 
2. MATERIALS AND METHODS 
The synthesis and purification of the 27-residue peptide was per- 
formed as described previously [16]. For ‘H NMR measurements, the
purified peptidc was dissolved in DMSO-d, at a concentration of 5 
mg/ml. One-dimensional spectral features in DMSO-d, showed little 
difference from those in *H20. 
Two-dimensional DQFCOSY, HOHAHA (r,,,,,%= 100 and 120 ms) 
and NOESY (z,,,,,~- -50, 150, 300 and 500 ms) measurements were 
performed at 37°C on a JEOL GX-400 spectrometer with a spectraI 
width of 5000 Hz and 2048 data points. Sixty-four scans were accumu- 
lated for each 256 column data under pre saturation of residual 
H’HO. 
3. RESULTS 
Sequence-specific ‘H NMR assignments [17] were 
carried out by a combined use of DQFCOSY, HO- 
HAHA and NOESY, and the results are summarized in
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Fig. I, A 2D HOHAHA spectrum (r”,,,= 120 ms) between the NH (7.6-8.4 ppm) and aliphatic protons (0.3-5.3 ppm) of the 27-residue peptide 
at 400 MHz. Specific signal assignments were obtained from sequential assignment. 
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Fig. 2. Summary of the assigned inter-residue NOE connectivities (-). 
The highly conserved residues are marked with asterisks(*). 
Table I. For residues Asp’-Sers, signal overlap and 
small NOE’s did not allow reliable sequential assign- 
ments. Fig. 1 shows a HOHAHA spectrum for the ali- 
phatic NH region. From studies with varied mixing time 
from 50 ms to 500 ms, 23 inter-residue NOES (including 
sequential ones) could be identified as summarized in 
Fig. 2. 
A notable feature in Fig. 2 is the presence of H,i-Hsi+, 
NOE connectivities between Ile’* and Pro” and between 
ProI and Pro20, which are derived from the spectrum 
shown in Fig, 3A. No Hori-Hai+, NOE connectivities 
were identified for these residues. These results indicate 
that the conformations of the two consecutive peptide 
bonds, Ile”-Pro’” and Pro’9-Pro20, are locked to tram 
[17]. Another notable feature of Fig. 2 is the presence 
of strong HNi-HNi+l NOE connectivities between Lys2’ 
and Tyr22 and between TyrZ2 and Arg” (cf. Fig. 3B). In 
addition, Ni-~i+l NOE was observed between Lys” and 
Tyr22. The observed inter-residue NOE’s, together with 
a relatively large coupling constant JNo for TyrZ2 (7.8 
Hz), suggest strongly that the peptide segment of Pro2’- 
Lys”-TyrZ2-Arg2” assumes a type I B-turn [17] with a 
hydrogen bonding between C=O of Pro2’ and NH of 
Arg23. 
Another strong HNi-HNi+, NOE connectivity was 
found between peaks at 8.14 ppm (assignable to Gly12) 
and 7.91 ppm (assignable to Lys13) (cf. Fig. 3B). This 
(6) 
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Fig. 3. (A) An NOE spectrum between the Pro a and 6 protons with a corresponding HOHAHA spectrum and (B) an NOE spectrum between 
the NH protons, all measured at 400 MHz. 
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Table I 
Summary of assigned ‘H chemical shifts of the 27-residue peptide 
having the sequence of exon I B of calpastatin 
Chemical shifts (ppm) 
Resi- NH a P others 
due 
6T 1.75 
7Y 7.83 
81 7.93 
9E 8.03 
IO E 8.12 
fl L 8.04 
12G 8.14 
13 K 7.91 
14 R 8.12 
15E 7.96 
16 V 7.98 
l7T 7.89 
18 I 7.73 
19P 
20 P 
21 K 8.01 
22 Y 7.67 
23 R 8.19 
24 E 8.32 
25 L 8.00 
26 L 7.86 
21 A 7.15 
4.22 
4.51 
4.15 
4.31 
4.44 
4.30 
3.74 
3.86 
4.36 
4.34 
4.37 
4.35 
4.34 
4.47 
4.62 
4.40 
4.19 
4.53 
4.34 
4.52 
4.4 
4.34 
4.26 
4.02 
4.02 
3.02 
2.81 
1.83 
1.99 
I .90 
2.11 
I .90 
1.55 
I .55 
I.78 
I .78 
I.80 
I .80 
I.88 
I .97 
I .70 
4.01 
4.01 
1.79 
2.22 
I .99 
2.10 
I .98 
1.68 
1.68 
2.79 
3.02 
I .80 
1.80 
2.18 
1.97 
1.55 
1.55 
2.25 
2.05 
1.38 
OH 4.90 
s 
E 
yCH3 
yCH3 
6CH3 
CO:H 
COLH 
6 
7.08 
7.38 
0.89 
I.51 
0.90 
2.35 
12.8 
2.50 
12.8 
1.55 
0.95 
; 
.? 
Y 
6 
E NH 
Y 
I .40 
I.61 
7.72 
I .59 
3.19 
7.51 
2.35 
COOH 
O’H 
12.8 
0.95 
4.90 
yCH3 
yCH2 
6CH3 
s’ 
: 
5 
E 
ENH~ 
ii 
& 
; 
&NH 
C&H 
z 
; 
0.90 
1.58 
0.95 
1.89 
3.85 
1.97 
3.12 
i.33 
1.56 
2.81 
7.72 
7.08 
7.38 
1.59 
3.19 
7.51 
2.56 
12.8 
1.55 
0.89 
2.05 
0.93 
7.08 
7.38 
0.89 
I.18 
2.36 
2.59 
0.90 
I .4l 
I.61 
1.61 
3.19 
2.35 
0.93 
0.87 
1.13 
1.90 
3.61 
1.88 
3.61 
1.34 
1.56 
2.81 
7.08 
7.38 
1.61 
3.19 
2.56 
0.94 
0.93 
indicates a possibility of another turn (Type II) [ 171 
involving Glu’“-Leu”-Gly’2-Lys’3. 
4. DISCUSSION 
Regular secondary 
sheet were not found 
66 
structures such as a-helix and p- 
for the active 27-residue peptide. 
The result appears to be consistent with the previous 
study on Domain 1 1131. However, the region from Ile” 
to Arg23 was clearly shown to have a restricted structure 
in which the conformations of the two consecutive pep- 
tide bonds, Ile”-Pro” and Pro’” Pro”, are locked to 
trans, and Pro*“-Lys”-Tyr” -Arg” forms a type 1 /3- 
turn. A most interesting point is that this region coinci- 
des almost perfectly with the region of the peptide 
Thr”-Arg” consisting of highly conserved residues 
(marked with asterisks in Fig. 2). A possibility of an- 
other turn was suggested for the region from Glu” to 
Lys”, which also contains a highly conserved residue, 
Gly12. These findings suggest strongly that the restricted 
structures formed by Ile’8~~Arg’3, and probably also by 
Glu”-Lys”, are essential for the specific interaction of 
calpastatin with calpain. From the present study combi- 
ned with the earlier results by Uemori et al. [13], we may 
conclude that, although the repetitive domain of calpa- 
statin does not have an extensive tertiary structure such 
as those found in most serine protease inhibitors [14] 
and cystatin [15], it would have a well-defined local 
structure essential for the specific interaction with cal- 
pain. 
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